The AL International Staging System (AL-ISS) integrates cardiac biomarkers and echocardiographic longitudinal strain to refine prognosis in systemic AL amyloidosis and define an ultra‑poor‑risk Stage IIIC with median survival of 7 months despite modern therapies.